Sanaka T, Sugino N, Teraoka S, Ota K
Kidney Center, Tokyo Women's Medical College, Japan.
Am J Kidney Dis. 1988 Aug;12(2):97-103. doi: 10.1016/s0272-6386(88)80002-7.
The present study was carried out to clarify whether an oral sorbent, AST-120 (Kureha Chemical Ind Co, Tokyo), may postpone the initiation of dialysis therapy. The subjects were randomly divided into two groups, control and AST. The AST group consisted of 27 undialyzed uremic patients. Serum creatine concentrations (SCr) were 4.3 to 8.1 mg/dL (5.8 +/- 1.1 mg/dL, mean +/- SD). The control group consisted of 24 uremic patients who were not given AST-120 during the conservative therapy period before the initiation of hemodialysis. AST-120 (3.2 to 7.2 g/d) was administered to the patients in the AST group for 2.4 to 30.1 months (13.2 +/- 7.4) before the initiation of hemodialysis. The slopes of reciprocal creatinine v time in the control group were -1,251 +/- 856 x 10(-5) dL/mg/month during the 6 to 12 months before the initiation of dialysis therapy, and in the AST group, they were -1,004 +/- 1,012 x 10(-5) dL/mg/month before administration, and -347 +/- 509 x 10(-5) dL/mg/month after administration of AST-120 (P less than 0.01). All 24 patients in the control group and 21 of 27 in the AST group were introduced to hemodialysis. SCr and serum urea nitrogen (SUN) at the initiation of hemodialysis did not differ between the control and AST group: 10.8 +/- 2.6 and 11.0 +/- 2.2 mg/dL and 92.7 +/- 22.2 and 94.1 +/- 21.6 mg/dL, respectively. The times to the 50% undialyzed level were 5.0 months in the control group, and 14.3 months in the AST group.(ABSTRACT TRUNCATED AT 250 WORDS)
本研究旨在阐明口服吸附剂AST - 120（东京吴羽化学工业株式会社）是否可以推迟透析治疗的开始。研究对象被随机分为两组，即对照组和AST组。AST组由27例未接受透析的尿毒症患者组成。血清肌酐浓度（SCr）为4.3至8.1mg/dL（平均±标准差为5.8±1.1mg/dL）。对照组由24例尿毒症患者组成，这些患者在开始血液透析前的保守治疗期间未给予AST - 120。在开始血液透析前，给AST组患者服用AST - 120（3.2至7.2g/天），持续2.4至30.1个月（平均13.2±7.4个月）。在开始透析治疗前的6至12个月期间，对照组中肌酐倒数与时间的斜率为 - 1,251±856×10⁻⁵dL/mg/月，在AST组中，给药前为 - 1,004±1,012×10⁻⁵dL/mg/月，给药后为 - 347±509×10⁻⁵dL/mg/月（P<0.01）。对照组的24例患者和AST组的27例中的21例开始接受血液透析。开始血液透析时，对照组和AST组的SCr和血清尿素氮（SUN）无差异：分别为10.8±2.6和11.0±2.2mg/dL以及92.7±22.2和94.1±21.6mg/dL。达到未透析水平50%的时间，对照组为5.0个月，AST组为14.3个月。（摘要截短至250字）
